Immune System Diseases

905 trials 381 recruiting

Filter these 905 trials by phase, country and sponsor.

Open in Search →

BEAT-GVHD (Belumosudil for acute/chronic GVHD overlap syndrome) Recruiting

2025-521940-39-00 steroid-refractory overlap syndrom Graft-versus-Host-Di 4 2026-01-20
A phase I/II study of CAR-T cells in AutoiMmune disease resistant to B cell Abrogation - CARAMBA Recruiting

2025-521530-28-00 Progressive systemic autoimmune disease resistant to B 9 2026-01-19
An open-label phase II trial to evaluate the clinical efficacy, safety and tolerability of MAS825 in pediatric and adult participants with S… Recruiting

2024-520208-25-00 Still’s disease 4 2026-01-15
A study to compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 with US-Dupixent®, and EU-Dupixent® in Healt… Recruiting

2025-523115-11-00 Phase I study in healthy participants. Intended indicat 1 2026-01-14
A study of belumosudil in children with chronic graft versus host disease (schoolROCK). Recruiting

2024-511508-18-00 Chronic graft versus host disease. 9 2026-01-05
Study of Q702 in Subjects with Relapsed or Refractory Chronic Graft-versus-Host Disease (cGVHD) Recruiting

2025-522680-14-00 Chronic Graft-versus-Host Disease 2 2025-12-23
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients with AChR+ Generalized Myasthenia Gravis Recruiting

2024-515157-17-00 Generalized Myasthenia Gravis with autoantibodies again 5 2025-12-22
A study to find how well budoprutug (TNT119) works and how safe it is in participants with immune thrombocytopenia Recruiting

2024-519745-30-01 Immune Thrombocytopenia (ITP) 9 2025-12-19
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Subjects With Primary Membranous Nephropathy Recruiting

2025-521661-27-00 Primary Membranous Nephropathy 10 2025-12-19
OBI-WAN : Obinutuzumab for remission induction in patients with relapsing PR3-ANCA granulomatosis with polyangiitis (Wegener’s). Phase 2 pro… Recruiting

2022-501557-36-00 PR3-ANCA granulomatosis with polyangiitis (Wegener’s) 4 2025-12-19
Dose Escalation Study with Bispecific Antibodies in Adult Patients with Lupus Nephritis Recruiting

2024-518288-37-00 Lupus Nephritis 3 2025-12-18
Justification AnD evaluation, in pOlymyalgia RhEumatica, of BARIcitinib versus placebo (JADORE-BARI study) Recruiting

2024-518385-26-01 Polymyalgia Rheumatica (PMR) 5 2025-12-18
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition Recruiting

2025-520825-19-00 IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (al 5 2025-12-16
Efficacy and Safety of IMVT-1402 in Adult Participants with Primary Sjogren’s Disease with Moderate to Severe Systemic Disease Activity Recruiting

2025-520831-18-00 Primary Sjogren’s Disease 4 2025-12-12
PROSPECTOR 2 Recruiting

2025-520888-41-00 Penicillin allergy 6 2025-12-10
A Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Participants with Multiple Sclerosis Recruiting

2024-517980-22-00 Multiple Sclerosis (MS) 4 2025-12-10
Evaluation of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF) Recruiting

2025-521278-32-00 Idiopathic Pulmonary Fibrosis (IPF) 4 2025-12-04
Efficacy and Safety of Icotrokinra in Participants with Moderately to Severely Active Crohn’s Disease Recruiting

2025-521382-27-00 Moderately to Severely Active Crohn's Disease 10 2025-12-04
A 52-week study of rilzabrutinib efficacy and safety compared to placebo in adults diagnosed with IgG4-related disease Recruiting

2025-521398-15-00 Immune system diseases 5 2025-12-04
A Phase 1 Study of the Safety and Preliminary Efficacy of CTX112 in Adult Subjects With Refractory Autoimmune Disease. Recruiting

2024-518528-54-00 Active systemic lupus erythematosus (SLE), systemic scl 1 2025-12-02
A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Safety of Epicutaneous Immunotherapy with DBV712 250 µg in 1-thr… Recruiting

2025-521697-34-00 Peanut allergy 5 2025-12-01
A Phase 2b Study of IMVT-1402 Treatment in CIDP Recruiting

2024-517614-14-00 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP 4 2025-11-28
A study to find how well budoprutug (TNT119) works and how safe it is in participants with Systemic Lupus Erythematosus Recruiting

2024-520385-57-01 Systemic Lupus Erythematosus 3 2025-11-26
Phase 2a Study of ALXN1920 in PMN Recruiting

2025-520780-40-00 Primary Mebranous Nephropathy (PMN) 4 2025-11-26